AptarGroup (ATR)
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-09-09
$122.11-1.79%
Close 2026-09-09 · 1-day change
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-09-09
Intact: The reason to own it still holds.
AptarGroup grows revenue about 11% year over year, reaching $983 million in Q1 2026. Profit margins remain stable with EPS guidance of $1.36 next quarter. The company steadily increases dividends to $0.48 per share. Cost management efforts continue despite slight operating income pressure.
Operating income declined from $113.4 million to $107.5 million in Q1 2026, showing limited profit improvement. Revenue growth could slow below the 5% consensus. Dividend growth may stall if cash flow weakens.
The price is about 14% above our fair value near $112, reflecting analysts' 5% revenue growth expectations. Our view aligns with this moderate growth but sees risks in profit margin pressure.
Breaks if: dividend per share falls below $0.48 next year
Breaks if: EPS guidance falls below $1.32 for 2026-Q2
Breaks if: operating income falls below $107M next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on steady revenue growth and dividend payouts. The current thesis state is intact, supported by recent strong financial results and management's commitment to growth.
The market currently reflects a neutral valuation with a slight premium compared to peers. There is an expectations gap, indicating that investors may not fully recognize the company's potential for growth and stability.
Management has successfully increased revenue across all segments, though operating income and margins have faced some pressure. The near-term risk of missing earnings remains low, but recent history shows potential for volatility.
The long-term thesis hinges on management's ability to maintain revenue growth, improve margins, and navigate potential risks like guidance cuts. Additionally, broader sector performance and inflation trends will play a crucial role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 5% next year
Focus on driving revenue growth across all segments, particularly in Pharma and Beauty.
Overall, ATR's fundamentals appear strong, but ongoing management execution and external factors will be key to its future performance. Not investment advice.